NDA 216018 · Spil
Aspruzyo Sprinkle
Ranolazine · Oral · Anti-anginal
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Feb 28, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
87
17 Phase 3, 3 recruiting
FAERS reports
10,544
9,584 serious, 1,344 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 29, 2025.
ASPRUZYO Sprinkle is indicated for the treatment of chronic angina. ASPRUZYO Sprinkle may be used with beta-blockers, nitrates, calcium channel blockers, anti‑platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. ASPRUZYO Sprinkle is an antianginal indicated for the treatment of chronic angina. (1)
Mechanism: The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (I Na ). However, the relationship of this inhibition to angina symptoms is uncertain. The QT prolongation effect of ranolazine on the surface electrocardiogram is the result of inhibition of I Kr which prolongs the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ASPRUZYO SPRINKLE · RANOLAZINE 500MG · GRANULE, EXTENDED RELEASE, ORAL · Discontinued
- ASPRUZYO SPRINKLE · RANOLAZINE 1GM · GRANULE, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ranolazine" as an intervention, any sponsor and status, largest first.
- Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary SyndromesPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00099788 · 6,560 participants · Start Oct 2004 · Primary completion Feb 2007
Drug: Ranolazine; Placebo · For: Myocardial Ischemia
Sites: Boston, Massachusetts
- Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01442038 · 2,651 participants · Start Oct 2011 · Primary completion Feb 2015
Drug: Ranolazine; Placebo · For: Coronary Artery Disease; Angina Pectoris
Sites: Birmingham, Alabama; Huntsville, Alabama; Scottsdale, Arizona · 218 sites in all
OBS PakistanIndustry
NCT03486561 · 2,000 participants (planned) · Start Apr 1, 2018 · Primary completion Sep 30, 2018
Drug: Ranolazine · For: Chronic Stable Angina
- Ranolazine Implantable Cardioverter-Defibrillator TrialPivotal-lookingCompleted
University of RochesterAcademic, hospital or other
NCT01215253 · 1,012 participants · Start Sep 2011 · Primary completion Feb 28, 2017
Drug: Ranolazine · For: Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy; Heart Failure
Sites: Tucson, Arizona; Little Rock, Arkansas; East Palo Alto, California · 90 sites in all
- Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01425359 · 949 participants · Start Sep 2011 · Primary completion Oct 2012
Drug: Ranolazine; Ranolazine placebo · For: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Sites: Little Rock, Arkansas; Merced, California; Moreno Valley, California · 135 sites in all
- Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With AmlodipinePivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00091429 · 500 participants · Start Aug 2004 · Primary completion Feb 2005
Drug: Ranolazine · For: Angina
- Ranolazine Monotherapy in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01472185 · 465 participants · Start Nov 2011 · Primary completion Oct 2013
Drug: Ranolazine; Placebo · For: Type 2 Diabetes Mellitus
Sites: Glendale, Arizona; Phoenix, Arizona; Tucson, Arizona · 159 sites in all
- A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AlonePivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01555164 · 442 participants · Start Jun 2012 · Primary completion Sep 2013
Drug: Ranolazine; Placebo to match ranolazine and 2 more · For: Type 2 Diabetes Mellitus
Sites: Gulf Shores, Alabama; Little Rock, Alaska; Chandler, Arizona · 146 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death831
- myocardial infarction650
- chest pain622
- angina pectoris599
- stent placement582
- dyspnoea447
- dizziness438
- fall387
- cerebrovascular accident356
- cardiac disorder311
- off label use302
- nausea292
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 15 |
| 2009 | 23 |
| 2010 | 33 |
| 2011 | 61 |
| 2012 | 115 |
| 2013 | 133 |
| 2014 | 548 |
| 2015 | 1,488 |
| 2016 | 1,180 |
| 2017 | 1,382 |
| 2018 | 1,435 |
| 2019 | 984 |
| 2020 | 331 |
| 2021 | 313 |
| 2022 | 370 |
| 2023 | 426 |
| 2024 | 516 |
| 2025 | 674 |
| 2026 | 507 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aspruzyo Sprinkle (Ranolazine)
2024 spending
$5K
Beneficiaries
17
21 claims
Per beneficiary
$283
$5.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $26,127 |
| 2023 | $138,947 |
| 2024 | $4,816 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
Ayyasamy L, Bagepally BS · Clin Ther 2023 · Meta-Analysis, Systematic Review
- QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients.
Goldenberg I, Aktas MK, Zareba W, et al. · JACC Clin Electrophysiol 2024 · Clinical Trial, Multicenter Study
- An updated review on therapeutic strategies in coronary microvascular dysfunction.
Khandkar C, Rehan R, Ravindran J, et al. · Int J Cardiol 2025 · Systematic Review, Meta-Analysis
- Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers.
Müller P, Draguhn A, Egorov AV · Pflugers Arch 2024 · Systematic Review
- Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis.
Guerra F, Romandini A, Barbarossa A, et al. · Int J Cardiol 2017 · Meta-Analysis, Systematic Review
- ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Sinha A, Rahman H, Douiri A, et al. · Circulation 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Spil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.